-
Innovation Ranking
NewInnovation Ranking – CTI BioPharma Corp
CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company that acquires, develops, and commercializes novel therapies for a range of blood-related cancers. Its lead product, Pacritinib is intended for the treatment of patients with myeloproliferative diseases. Its product pipeline includes PACIFICA for the treatment of myelofibrosis patients with severe thrombocytopenia; PAC203 for the patients with ruxolitinib therapy failure; PRE-VENT for COVID-19; PERSIST 1 for all platelets count and PERSIST 2 for platelets counts less than thousand. Its commercialized product, Vonjo...
-
Company Insights
Innovation and Patenting activity of CTI BioPharma Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CTI BioPharma Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Sector Analysis
NewAmericas Fibercos and Towercos Market Dynamics and Opportunities
Fibercos and Towercos: Market Dynamics and Opportunities in the Americas,’ a new Telecom Insider Report by GlobalData, provides an executive-level overview of the fiberco and towerco state of play, developments, and strategies, including in the context of 5G and fiber network deployments. This report highlights the main drivers for the emergence and growth of towercos and fibercos in the Americas, gives an overview of the key models for towercos and fibercos in the region, deep dives into the latest developments...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CGX-1321 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CGX-1321 in Esophageal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CGX-1321 in Esophageal Cancer Drug Details: CGX-1321 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacritinib in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacritinib in Graft Versus Host Disease (GVHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Graft Versus Host Disease (GVHD) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacritinib in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Peripheral T-Cell Lymphomas (PTCL) Drug Details: PacritInib (Vonjo)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Cutaneous T-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacritinib in Cutaneous T-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Cutaneous T-Cell Lymphoma Drug Details: PacritInib (Vonjo) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Mycosis Fungoides
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacritinib in Mycosis Fungoides report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Mycosis Fungoides Drug Details: PacritInib (Vonjo) is an anti neoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Sezary Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacritinib in Sezary Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Sezary Syndrome Drug Details: PacritInib (Vonjo) is an anti neoplastic...